In order to evaluate an x-fold increase in TGFβ1-triggered expression of αSMA (CMHDF, rTGFβ1; CMSCL) in comparison with mock-treatment (CMHDF), subconfluent HDF were treated with recombinant- and tumour cell-derived TGFβ1. Here, ACTA1 is linked to neoplasm.